Mylan launches generic Gleevec
HERTFORDSHIRE, England, and PITTSBURGH — Mylan is expanding its offering of oncology generics with its latest introduction. The company has launched its generic of Gleeven (imatinib mesylate) tablets.
The drug is approved to treat multiple indications, including several blood cancers, the company said. The drug had U.S. sales of approximately $1.7 billion for the 12 months ended July 31, according to QunitilesIMS data. The product will be available in 100- and 400-mg dosage strengths.
No comments found